Operating CF
$294.86M
Capex
−$25.26M
Free Cash Flow
$269.60M
FCF Margin
+91.4%
Cash flow waterfall for Bio-Techne (TECH) — TTM through Q1 2026
Free cash flow: $269.60M
Cash flow breakdown for Bio-Techne (TECH) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $294.86M | $294.86M |
| Capital Expenditure | −$25.26M | $269.60M |
| Free Cash Flow | $269.60M | $269.60M |
| Acquisitions | $4.62M | $274.21M |
| Other Investing | $9.92M | $284.13M |
| Share Buybacks | −$100.08M | $184.05M |
| Dividends Paid | −$49.82M | $134.23M |
| Net Debt Change | −$130.00M | $4.23M |
| Other Financing | $53.54M | $57.77M |
| Forex Effect | $11.38M | $69.15M |
| Net Cash Increase | $69.15M | $69.15M |
- Operating Cash Flow$294.86M
- Capital Expenditure−$25.26M
- Free Cash Flow$269.60M
- Acquisitions$4.62M
- Other Investing$9.92M
- Share Buybacks−$100.08M
- Dividends Paid−$49.82M
- Net Debt Change−$130.00M
- Other Financing$53.54M
- Forex Effect$11.38M
- Net Cash Increase$69.15M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Bio-Techne (TECH) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement